RecruitingPhase 1NCT07025538

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
City of Hope Medical Center
Principal Investigator
Amandeep Salhotra
City of Hope Medical Center
Intervention
Best Practice(other)
Enrollment
42 target
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07025538 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials